Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

2.4%

1 terminated/withdrawn out of 42 trials

Success Rate

97.6%

+11.1% vs industry average

Late-Stage Pipeline

40%

17 trials in Phase 3/4

Results Transparency

37%

15 of 41 completed trials have results

Key Signals

15 with results

Enrollment Performance

Analytics

Phase 1

14(34.1%)

Phase 3

11(26.8%)

Phase 2

9(22.0%)

Phase 4

6(14.6%)

N/A

1(2.4%)

41Total

Phase 1(14)

Phase 3(11)

Phase 2(9)

Phase 4(6)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (42)

Showing 20 of 42 trials

NCT02543268Phase 3Completed

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Role: lead

NCT01366534Phase 2Completed

Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults

Role: collaborator

NCT01938352Phase 2Completed

Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza Challenge

Role: lead

NCT01307436Phase 3Completed

Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccines

Role: lead

NCT02218125Phase 1Completed

A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults

Role: lead

NCT02440035Phase 1Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Participants

Role: lead

NCT02313077Phase 1Completed

A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Role: lead

NCT02376400Phase 1Completed

A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Role: lead

NCT02376426Phase 1Completed

A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Role: lead

NCT02561871Phase 1Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers

Role: lead

NCT01017536Phase 2Completed

Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults

Role: collaborator

NCT02304185Phase 1Completed

Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult Volunteers

Role: lead

NCT02414828Phase 2Completed

A Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary TB

Role: collaborator

NCT02148328Phase 1Completed

Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults

Role: lead

NCT01683773Phase 1Completed

Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A

Role: collaborator

NCT01839760Completed

Evaluation of Viral Shedding Patterns and Clinical Outcomes of Influenza Patients

Role: lead

NCT01617239Phase 1Completed

Clinical Study for Safety and Immunogenicity Study of Influenza Vaccine

Role: lead

NCT01405677Phase 2Completed

Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine

Role: lead

NCT01917357Phase 3Completed

A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject

Role: lead

NCT01992276Phase 2Withdrawn

Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection

Role: lead